Sustained maintenance of therapeutic levels of angiostatic proteins in tumor tissues continues to represent a major challenge to antiangiogenesis therapy of cancer. In this study, we tested the hypothesis of utilizing gene transfer via replication-competent retroviral (RCR) vectors for chronic protein delivery. We now show that bioactive human interferon-inducible protein-10 (IP10) can be secreted from a variety of mammalian cells upon transduction with RCR vectors carrying the human IP10 gene. The production of IP10 from RCR-transduced cells could be maintained for at least three months in culture. The level and duration of IP10 expression in vivo was sufficient to inhibit growth of subcutaneous (s.c.) tumors as well as metastatic lesions in mice. This tumor inhibition was correlated to a marked reduction in tumor vascularization and mitotic activity. By conducting immunohistological studies, we have been able to show that IP10 vector-affected tumors evidenced elevated levels of IL-12p35 mRNA, with no sign of changes in the local inflammatory response, however, as determined by macrophage infiltration and the expression of proinflammatory cytokines. We are addressing the feasibility of using RCR vector-based gene therapy as a more convenient alternative tool to chronically deliver antiangiogenic proteins for cancer therapy.
A ngiogenesis is vital and rate-limiting to cancer progression, since an avascular tumor cannot grow to a size of clinical detection. [1] [2] [3] [4] Tumors appear to activate angiogenesis by changing locally the balance between positive and negative regulators of the angiogenic response. For example, many solid tumors evidence an overexpression of vascular endothelial growth factor (VEGF) and/or fibroblast growth factors (FGFs), which stimulate endothelial cell mitosis, migration, and survival. In others, the angiogenic response is associated with the downregulation of endogenous inhibitors (e.g., thrombospondin-1), with or without increased expression of angiogenic activators. [1] [2] [3] [4] Accordingly, intensive efforts are currently under way to evaluate, both experimentally and clinically, the effective use of different angiostatic agents as a novel cancer treatment modality. 1, 2, [5] [6] [7] [8] [9] [10] The interferon (IFN)-g-inducible protein 10 (IP10) is one of the CXC chemokines that lack the sequence GluLeu-Arg (ELR motif) at their NH2-terminus. 11, 12 Unlike ELR þ CXC chemokines, IP10 is a potent inhibitor of angiogenesis, tumor growth, and metastasis. [13] [14] [15] [16] It exerts angiostatic activity by inhibiting endothelial cell migration, [13] [14] [15] [16] [17] proliferation 18 or differentiation 19 induced by either ELR þ CXC chemokines or bFGF and VEGF. In addition, IP10 elicited thymus-dependent antitumor immunity 15, 20 and was found to be crucial for IL-12-mediated antitumor activity in some models. 21 Such an effect appears to be mediated by IP10 binding to and activating its CXCR3 receptor, which is expressed on activated T cells, preferentially of the Th1 phenotype, and on natural killer (NK) cells. 11, 12, [22] [23] [24] This dual antitumor mechanism of IP10 (angiostatic and immuno-stimulatory) makes it an attractive therapeutic candidate for cancer intervention. Recent studies have investigated the use of IP10 gene therapy using adenoviral vectors 25, 26 or retrovirally transduced tumor cells. 27 Overall, an emerging picture from these and other 5, 6, 9, 10, 28, 29 studies indicates that optimal IP10 therapy requires sustained maintenance of therapeutic levels of the protein in the tumor bed. However, repeated cycles of angiostatic therapy present a major challenge for both, protein-based angiostatic therapy (e.g., cost-intensive, inconvenient) and current gene delivery systems. 6, 30, 31 Therefore, alternative strategies are needed for chronic protein delivery.
The present study was designed to evaluate in vivo IP10 gene therapy utilizing replication-competent retroviral (RCR) vectors. Our hypothesis is that RCR vectors such as those derived from murine leukemia virus (MLV) are less immunogenic, efficiently integrate into chromosomes of host cells, and infect solely mitotically dividing cells, thus holding natural selectivity for tumor and angiogenic endothelial cells. Furthermore, spreading of RCR vectors from initially infected cells to their progeny and neighboring cells will amplify the transgene expression 32 and thus achieve higher transduction efficacy than conventional viral vectors. 33 Moreover, chronic and efficient delivery of the therapeutic proteins in the tumor environment can be expected. In fact, it is technically possible to generate MLV-based RCR vectors with infectivity and genomic stability. 34 We have recently shown that therapeutic proteins can be fused to the N-terminus of the MLV envelope protein (Env) via a furin cleavage site selected from retroviral libraries. 35 Owing to the ubiquitous expression of furin, considerable amounts of extracellular active therapeutic proteins, as for example, cytokines or functional antibody fragments (scFvs), are released from cells infected with this type of RCR.
In this study, MLV-derived RCR vectors encoding human IP10 were generated. Tumor transplants formed by IP10 vector-transduced cells exhibited markedly reduced growth in xenograft and syngeneic mouse models associated with a marked reduction in microvessel density. In situ overexpression of RCR-delivered IP10 led to an elevated level of IL-12p35 subunit mRNA in relevant tumor tissues, but, without affecting the local inflammatory response, such as macrophage infiltration and the expression of a set of proinflammatory cytokines. These results indicate that RCR vector-mediated expression of antiangiogenic protein(s) could be an attractive approach for gene therapy of cancer.
Materials and methods

Construction of human IP10-encoding RCR vectors
A cDNA coding for human IP10 was amplified from the pBLAST-hIP10 expression plasmid (InvivoGen) by polymerase chain reaction (PCR) with the following forward (cgaagcggcccagccggccgtacctctctctagaactgtac) and reverse primers (cgaagctgcggccgcccgcttgctcctgctaccaccaggagatcttt tagacctttcc). Incorporated SfiI and NotI restriction sites are underlined and, the coding sequence for the furin cleavage site (RLRRGSR) is shown in italics. After vector digestion and gel purification, the PCR fragment was cloned into the SfiI/NotI digested pE-A 36 to give the RCR vector IP10-A (Fig 1a) . To exchange the amphotropic 4070A env gene in IP10-A against that of the GaLV, the GaLV env reading frame was amplified by PCR using the primers GaLV/NotI( þ ) 5 0 -AAATTTAAAGCGGCCGC GAGTCTGCAAAATAAGAACCCC-3 0 and GaLV/ClaI(-) 5 0 -ATATAT ATCGAT TTAAAGGTTACCTTCGTTC TCTAG-3 0 and the GaLV env gene as template. PCR was carried out with AmpliTaq DNA polymerase (Eppendorf) for 15 cycles using 100 ng template DNA under the following conditions: 951C denaturation for 4 minutes, 501C annealing for 45 seconds, and 721C extension for 1 minute. The PCR fragment was then digested by NotI/ ClaI and cloned into pCD40L-A. 36 The human IP10 reading frame was finally inserted via the single SfiI/NotI sites, resulting in pIP10-G.
Cell lines and transfections
Human embryonic kidney cells (HEK-293T), HT1080 (human fibrosarcoma), B16F10 (murine melanoma), and LLC (murine lewis lung carcinoma) cells were obtained from the American Type Culture Collection. Cells were grown in DMEM medium supplemented with 10% FCS and 4 mM L-glutamine, and 1% penicillin/streptomycin. Primary human umbilical vein endothelial cells (HUVECs) were isolated by perfusing umbilical cords with collagenase type IV (Sigma-Aldrich) (0.2% in Hanks' balanced salt solution) at room temperature (RT) for 20 minutes. The cells were then cultivated in endothelial cell basal medium (PromoCell) supplemented with 2% FCS, 0.4% ECGS/H, 0.1 ng/ml epidermal growth factor, 1 ng/ ml basic fibroblast growth factor, 50 ng/ml amphotericin B, 50 mg/ml gentamicin, and 1 mg/ml hydrocortison. Infectious IP10-A and IP10-G RCR particles were generated by transient transfection of HEK-293T cells. Briefly, HEK-293T cells preseeded overnight in 100 mm diameter Petri dishes at 3 Â 10 6 cells/dish were transfected with 6 mg of retroviral plasmid (pIP10-A, pIP10-G) by use of 60 ml of Lipofectamine (#10964-013, GIBCO BRL) in 6 ml of serum-free DMEM. After 4-5 hours of incubation at 371C, transfection supernatant was removed and cells were further cultivated in 12 ml of complete medium at 371C in a humidified 5% CO 2 atmosphere. At 30 hours after transfection, culture medium was replaced with fresh DMEM without FCS; Afte 24-48 hours, the conditioned media containing RCR particles were harvested, passed through 0.45 mm pore-size filters, and stocked at À801C until further use. The same protocol was used to produce MLV-RCR vectors containing the gene for the scFv-L36 34 and wild-type MLV.
Transduction of cells with RCR vectors
To transduce tumor cells, 1 ml of filtered supernatant was layered over HT1080, B16F10 and LLC target cells that had been plated into six-well culture plates at 2 Â 10 5 cells per well the day before infection. Polybrene (8 mg/ml, Sigma Chemical Co.) was added to the wells. After 4-5 hours at 371C, supernatant was replaced by 3 ml of medium. Cells were kept in culture until confluence and expanded over time in T75 tissue flasks. The percentage of IP10 vector-infected cells was determined 1 week after infection, by immunohistochemistry using goat antiRLVgp30 serum (Quality, Biotech) as previously described, 36 and was constantly 100%.
Immunological detection of IP10 and retroviral Env proteins
For Western blot analysis, IP10 released into the cell culture supernatant was concentrated by TCA precipitation. For this purpose, 300 ml FCS free supernatant was mixed with 300 ml TCA, incubated for 30 minutes on ice, and centrifuged at 13,000 rpm for 20 minutes. The pellet was washed with acetone, air dried, dissolved in SDS sample buffer and the proteins separated on a 15% SDS-polyacrylamide gel. Medium alone and recombinant human IP10 protein (Cell Science Inc., MA) were used as negative and positive controls, respectively. Virus particles were pelleted from cell culture supernatant by ultracentrifugation (SW40, 30,000 r.p.m., 1 hour) and resuspended in 200 ml SDS sample buffer. Extracts of infected cells were prepared by lysing about 10 6 cells in 300 ml RIPA buffer (25 mM Tris pH 8, 137 mM NaCl, 10% glycerol, 0.1% SDS, 0.5% NaDOC, 1% NP40, and 2 mM EDTA) and removing nucleic acid by the QIAshredder column (Qiagen, Cat. No. 79654) according to the manufacturer's instructions. Viral proteins were separated on a 11% SDS-polyacrylamide gel. Separated proteins were electro-blotted (120 mA, 1 hour) to a nitrocellulose membrane (Hybond ECL, Amersham). The membrane was blocked with 10% horse serum (Sigma) in TBST containing 0.05% Tween 20 at RT for 1 hour. Immunoprobing was performed by incubation overnight at 41C with affinity-purified goat anti-human IP10 polyclonal antibody (0.1 mg/ml, diluted in TBST/5% horse serum, AF-266-NA, R&D Systems), anti-RLVgp70 goat antiserum (1:5000, diluted in TBST/5% horse serum, ATCC), or anti-RLV p30 goat antiserum (1:10000, diluted in TBST/5% horse serum, ATCC), followed by incubation (2.5 hours, RT) with a 1:10,000 dilution of HRPconjugated rabbit anti-goat IgG (P 0449; DAKO) in TBST/5% horse serum. After washing, the blot was developed using an ECL chemiluminescence detection kit (Pierce).
The levels of human IP10 in supernatants of the transduced tumor cells or in the sera of tumor-bearing mice were quantified with a commercially available human IP10 ELISA kit (#HK311, Sanbio Deutschland GmbH, Beutelsbach, Germany), according to the manufacturer's instructions.
In vitro angiogenesis assay
Matrigel basement membrane matrix (10 mg/ml, Becton Dickinson, Heidelberg, Germany) was plated into a prechilled (À201C) 24-well plate at 300 ml/well and allowed to gel at 371C for 60 minutes 6 Â 10 4 HUVECs per well resuspended in conditioned supernatants of transfected cells were then layered on top of the polymerized gel and incubated at 371C. After 24 hours, photographs were taken on a ZEISS inverted microscope. Capillary tubes were defined as cellular extensions linking cell masses or branch points.
In vitro proliferation assay and MTT assay
The effects of RCR-delivered IP10 onto the growth of HUVECs were evaluated in 12 consecutive days' culture by trypan blue exclusion assay. HUVEC cells were placed in triplicates in 3 ml of complete medium in fibronectincoated six-well plates (NUNC, Roskilde, Denmark) at a density of 1.3 Â 10 5 cells/well and were incubated with or without supernatants of cells transfected with pIP10-A or pIP10-G. After 4-5 days, the medium was removed, and attached cells were detached by trypsin/EDTA and stained with trypan blue. The live cells were counted using a hemacytometer and subjected to subpassage under the above conditions. A total of three cell subpassages were repeated within 12 consecutive days. Results were expressed as mean value of total cell number of HUVECs at each time point. Proliferation of IP10 vector-transduced tumor cells was analyzed daily for four consecutive days in MTT assays. 37 Briefly, cells were seeded in triplicate in 96-well plates at a density of 3 Â 10 3 cells/well. The living cell number was assessed at 24 hour intervals by adding 50 ml of 2 mg/ml MTT (M-5655, Sigma-Aldrich Chemie GmbH., Steinheim) to each well and incubating at 371C for 4 hours. The MTT reduced by living cells into a blue formazan product was solubilized in DMSO (150 ml/well), and read with a multiwell scanning spectrophotometer (Thermo Labsystems at 540 nm).
Tumor growth in vivo
Experimental mouse work was carried out in compliance with the regulations of the German animal protection law. Normal 6-to 8-week-old female C57BL/6 and SCID mice were purchased from Harlan Winkelmann GmbH (Borchen, Germany) and maintained under pathogenfree conditions (SCID mice). Animals were acclimated for at least 1 week before the start of the study.
Tumors (HT1080 or LLC) were established by subcutaneous injections of 5 Â 10 5 tumor cells in 100 ml of PBS in the left flank of mice. Tumors were measured with electronic calipers at regular intervals for 30-33 days, and tumor volumes were calculated according to the following formula: volume (mm 3 ) ¼ width 2 Â length Â 0.52, where 0.52 is a constant to calculate the volume of an ellipsoid. All animals were followed for general appearance and behavior such as ruffling of fur and neuromuscular performance. Each group consisted of six mice.
To establish melanoma metastases in the lung and elsewhere, 2 Â 10 5 B16F10 cells in 0.2 ml of PBS solution without Ca 2 þ or Mg 2 þ were injected into the tail veins of mice. Fourteen days after tumor cell implantation, mice were sacrificed and different organs (lung, liver, spleen, heart, kidney, and brain) were isolated to analyze the gross pathology and to determine the number of metastases appearing as black foci on the organ surface.
The statistical significance of differential findings between experimental groups of animals was determined by the two-sided Student's t-test. Findings were regarded as statistically significant if P-values were r.05.
Immunohistochemistry of s.c. tumors
Tumor tissue was snap-frozen in 2-methylbutane precooled on dry ice and stored at À801C. To measure DNA synthesis in tumor tissues, mice were intraperitoneally injected with 60 mg/g of body weight of BrdUrd (Sigma) in PBS, 1 hour prior to sacrifice. Frozen sections (5 mm in thickness) were cut on a cryostat and processed for immunohistochemistry by standard procedures. Sections were fixed in cold acetone for 20 minutes, followed by quenching of endogenous peroxidase with 0.3% H 2 O 2 in methanol (30 minutes, RT). Nonspecific binding was blocked with 10% species-specific serum in PBS/1% BSA. Then, sections were given with a two-step incubation, first with primary antibody (1:100, RT, 1 hour) and then with biotinylated species-appropriate secondary antibody (1:50, RT, 1 hour). Immunostaining was accomplished via exposure of slides to avidin-biotin-peroxidase complex and 3,3-diaminobenzidine (DAB) as the chromogen (BD PharMingen). Sections were lightly counterstained with Mayer's hematoxylin and mounted in Glycergel. The primary antibodies used had the following specificities: mouse CD4, CD8, CD31 (#550278, #550281, #550274, respectively, PharMingen), F4/8 (ab6640, Abcam Ltd, Cambridge, UK), and human IP10 (#500-P93, PeproTech EC Ltd, London, UK). Parallel negative controls without primary antibodies were run in all cases. All incubations were followed by three washing steps in PBS (pH 7.2). Quantitation of microvessel density was performed on tumors, with the three median volume measurements in each group, according to the procedures described by Weidner et al. 38 Only good-quality sections with uniform, well-demarcated staining and low background were analyzed. Immunostaining for BrdUrd was accomplished using the mouse to mouse in situ BrdU Detection Kit (#HCS30, Oncogene), following the manufacturer's protocol.
RT-PCR analysis of cytokines and chemokines
Total RNA was isolated from tumor tissues using RNeasy Protect Mini Kit (Qiagen) according to the manufacturer's instructions. One microgram of total RNA was digested with RNase-free DNase (1 Unit, 371C, 30 minutes, #M6101, Promega) and used for the synthesis of first-strand cDNA using specific primers as shown in Table 1 and Moloney MLV reverse transcriptase (SuperScript II, Invitrogen) in 20 ml reaction volume. About 4 ml of cDNA was amplified by PCR using specific primers listed in Table 1 , for 35 cycles at 951C for 45 seconds, appropriate annealing temperature for 45 seconds, and 721C for 1 minute. The amplification cycles for mouse G3PDH, IL-4, and IFN-g were 25, 45, and 45, respectively. Aliquots of the amplified products were run on a 2% agarose gel and photographed.
Results
Generation and characterization of RCR vectors expressing human IP10
Two types of IP10-expressing RCR vectors, IP10-A and IP10-G, were constructed (Fig 1a) . Both were derived from the genome of Moloney murine leukemia virus (MoMLV). To redirect the viral tropism to human cells, the MoMLV env gene was substituted against that of the amphotropic 4070A MLV (wt MLV) or that of the gibbon ape leukemia virus (GaLV). While wt MLV readily infects human and murine cells, the latter are usually nonpermissive for GaLV. The IP10 reading frame was modified with a furin cleavage site at its 3 0 -end and then inserted between the 3 0 -codon of the Env signal peptide and the 5 0 -codon of the Env SU subunit. We expected that the furin cleavage site will cause release of IP10 from the Env protein precursor molecule during transport to the cell surface and then secretion of IP10 from the infected cell. A second furin cleavage site exists naturally in retroviral Env proteins between the SU and TM subunits (Fig 1a) .
The RCR vectors were produced by transient transfection of 293T cells with plasmids pIP10-A and pIP10-G. Transfected cells were maintained in culture for 3-4 days, to maximize the fraction of transduced cells. By then, all cells were IP10 vector-positive as determined by staining infected cells for the MLV capsid antigen p30 (data not shown). The processing and production of human IP10 was subsequently investigated by Western blot analysis of cell lysates and cell culture supernatant. As controls, cells infected with wt MLV and or an MLV-based RCR vector expressing the antibody fragment L36 in place of IP10 were used. 34 In cell lysates, the antiserum directed against the wt MLV SU protein readily detected the IP10-Env precursor polypeptide migrating with a reduced mobility compared to the wt MLV Env precursor and the fully processed SU (bottom band) (Fig 1b, lanes 2 and 3) . In correspondence with the about doubled size of L36 compared to IP10, the mobility of the L36-Env precursor was even slower (lane 1). Western blot analysis using a human IP10-specific antibody confirmed these findings (data not shown). In contrast to the cell lysates, the supernatants of IP10-A transduced cells contained only the fully processed SU protein, demonstrating that the Antiangiogenic gene therapy using RCR vector Y Sun et al IP10-Env precursor protein was completely cleaved during transport to the cell surface, whereas the L36-Env protein was only partially cleaved (Fig 1b, lanes 6  and 7) . Comparison of the Env signal intensities to those of the capsid p30 protein for the IP10-A and the WT viruses, respectively, revealed that the Env incorporation was almost unimpaired for the IP10-A virus (Fig 1b, lanes  6 and 8) .
The levels of retrovirally derived human IP10 in conditioned medium from 293T transduced cells were initially estimated by Western blot analysis of supernatants from IP10-A and IP10-G transduced cells, respectively. Compared to bacterially produced IP10 that was used as a standard, similar levels of IP10 were detected in both cell supernatants ranging from 8-16 ng/ml (Fig 1c) . The IP10 produced by IP10 vectortransduced HT1080, LLC and B16F10 cells was measured by ELISA. This assay showed that similar IP10 levels (22-40 ng/ml) were present in the supernatants of 1 Â 10 6 of these cells at 24 h (data not shown). Repeated sampling of supernatants showed that IP10 production was stable, with no apparent reduction even after 90 days in vitro culture (data not shown). Neither HT1080 nor LLC and B16F10 cells themselves released detectable amounts of human IP10 into the culture medium.
In vitro function of retrovirally derived human IP10
To determine whether IP10 delivered by RCR vectors was biologically active, we tested IP10-containing viral supernatants in in vitro endothelial cell proliferation assay. We found that human IP10 viral supernatants had no measurable effect on the proliferation of primary endothelial cell (HUVEC) (Fig 2a) . In agreement with our data, previous studies with recombinant IP10 have also shown the lack of inhibitory effects of this protein on the growth and survival of a variety of endothelial cell lines, even at a dose of 2 mg/ml. 19 However, contradictory results exist. 18, 26 To assess whether RCR-delivered IP10 interferes with the differentiation of endothelial cells into tube-like structure, HUVEC cells were cultivated on a Matrigel substrate for 18-24 hours in the presence or absence of the conditioned culture medium containing IP10. As shown in Figure 2 , without retrovirally delivered IP10, cells rapidly aligned with one another and formed an intricate network of tube-like structure (Fig 2b) . However, in the presence of IP10-containing viral supernatants, endothelial cells formed small aggregate structures, and the network of tube-like structures was strikingly less extensive than in control cultures (Fig 2c) , suggesting that retrovirally derived IP10 could exert an antiangiogenic effect in vivo by disruptive tube-like structure formation.
Subcutaneous (s.c.) growth of HT1080 and LLC tumors in mice
To investigate whether RCR vector-delivered IP10 can inhibit tumor growth in vivo, we first tested whether expression of IP10 by IP10 vector-transduced tumor cells might have affected in vitro growth kinetics. In agreement with previous studies, 27 all three tumor cell lines (HT1080, LLC, B16F10) transduced with IP10 vectors showed tumor growth kinetics similar to that of parental cells (data not shown). A parallel examination of cell viability via Trypan blue exclusion assay revealed no appreciable differences among different samples (data not shown). Fig 3a) , demonstrating a therapeutic effect of retrovirally derived IP10.
To examine whether the in vivo angiogenesis effect of IP10 can be reproduced in immuno-competent animals, we s.c. implanted parental, wt-, or IP10-A-transduced LLC cells in C57BL/6 mice and compared their growth. Since IP10 has dual antitumoral effects, [13] [14] [15] [16] [17] [18] [19] [20] [21] it was expected that greater tumor inhibition should be observed in this experimental setting. As shown in Figure 3b (S.E.) for IP10-A-LLC tumors (P ¼ .0001, unpaired Student's t-test). However, no complete inhibition was noted (Fig 3b) . Nonetheless, these results demonstrate that RCR vector-delivered IP-10 can inhibit tumor growth in vivo in both immunocompromised and immuno-competent conditions.
Metastatic tumor growth of B16F10 cells
To evaluate whether IP10 delivery by RCR vectors could inhibit tumor formation in a metastatic model, we performed a single-tail vein injection of B16F10 cells and cells transduced with IP10-A, or wt MLV. The B16F10 model was chosen primarily based on its gross visibility of metastases in different organs. At 2-weeks after tumor implantation, mice receiving parental (n ¼ 6) or wt-B16F10 cells (n ¼ 6) all developed visible lung metastases, with the number ranging between 1 and 3 metastases per lung. Furthermore, 50% (three of six) of animals given parental cells succumbed to metastases in the spleen but not in other organs (Fig 3c, and data not  shown) . In contrast, four of the six mice given IP10-Atransduced B16F10 cells were free of metastases in gross pathology of the lung and spleen, or elsewhere, at two weeks after i.v. tumor cell implantation. The total number of macrometastases in mice receiving IP10-A-transduced cells was only 25% of that in control mice (Fig 3c) . These results suggest that transduction with IP10 vector can prevent mice from metastatic tumor growth in different organs.
Histological studies
To analyze the levels of vascularization of s.c. HT1080 tumors, frozen sections of tumor explants were prepared at day 30 postimplantantion and immunohistochemically stained for mouse CD31 antigen. Control tumors displayed larger capillaries of different shapes and thickness of vessel walls (Fig 4, panel a) . In contrast, IP10-G-affected tumors appeared less vascularized. The number of microvessels in IP10-G-affected tumors was ) cells alone (parental) or transduced with either wt-MLV (wt) or the IP10-A (IP10-A) vector were implanted intravenously into C57BL/6 mice via tail-vein injections. At 14 days after injection, mice were killed and mouse organs (i.e., lung, spleen, liver, heart, kidney, and brain) isolated for gross pathology. Metastatic lesions appearing as black foci on the organ surface were counted. Data shown represent the total number of metastases in lung and spleen in each group (six animals/group). The total number of lung macrometastases was 16, 13, and 3 for the parental, wt-, and the IP10-A group, respectively. Note that half (50%) the mice given parental tumor cells concomitantly developed macrometastases in the spleen. (Fig 4, panels b and e) . From these results, we conclude that the antitumoral effect of RCR-delivered IP10 observed above are due, at least in part, to the reduced level of vascularization of tumors. Different approaches were employed to confirm human IP10 production in vivo. Total RNA isolated from tumor tissues was subjected to RT-PCR amplification of the human IP10-encoding region. IP10 expression was detected exclusively in xenografts formed by IP10 vector-transduced HT1080 cells (data not shown). The same was true for syngeneic LLC tumors (data not shown). This indicated that the transgene was transcriptionally active in vivo, and the viral promoter was not silenced in this system. Immunohistochemical staining of the same tumor samples with human IP10-specific mAb revealed that this angiostatic protein was in fact produced in the IP10 vector-transduced, but not the control tumor samples (Fig 4, panel c) . In agreement with these results, a significant amount (15-36 ng/ml) of RCR-delivered IP10 was detected in the serum of each mouse inoculated with IP10 vector-transduced tumor cells (Fig 4f) . None of control mice showed detectable amounts of human IP10 under our assay conditions.
Immunological characterization of IP10-A-transduced LLC tumors
To clarify whether the antitumoral effect of IP10 in our syngeneic model was partially ascribed to its action of recruiting effector T cells, frozen sections of parental, IP10-A-and wt-affected LLC tumors were immunohistochemically stained for mouse CD4 and CD8 T-cell antigens. Parental tumors showed tiny numbers of CD4-and CD8-stained T cells throughout the tumor sections (Fig 5a, upper and middle panels) . Although increased number of T cells, especially CD4 þ T-cell subset was detected sporadically as a few 'islets' throughout sections of IP10-A-LLC tumor samples, no appreciable differences in the quantity were observed between these and wttransduced LLC tumors (Fig 5a, upper and middle  panels) . This implied that IP10 did not appear to quantitatively affect T-cell infiltration in these transduced tumors. Parallel staining of the same tumor samples with antiF4/80 mAb revealed that each of these tumors had a massive infiltrate of macrophages (Fig 5a, low panel) . These results are consistent with the notion that tumorassociated macrophages (TAMs) are a major component of the infiltrate of most, if not all, tumors. [39] [40] [41] No appreciable differences in TAMs infiltrate existed among different tumors, suggesting that the plausible release of RCR vector particles from transduced cells did not augment inflammatory responses.
To examine the possible functions of these immune/ inflammatory cells, we examined mRNA by RT-PCR analysis of an array of mouse cytokines and chemokines associated with Th 1 and Th 2 phenotypes. 11, 39, 41 A total of 2 parental, 3 wt-and 3 IP10 vector-affected tumors were included (Fig 5b) . Tumor RNA was pretreated with DNase I to remove any residual genomic DNA that could generate PCR products related to target gene presence rather than expression. Neither IFN-g nor IL-4 expression was detected, although a marginal level of IFN-g was noted in one IP10 vector-affected tumor (Fig 5b, and data  not shown) . In contrast, IL-10 and murine IP10 were significantly expressed in most tumor samples analyzed, when referring to G3PDH levels, and at similar levels among different groups. Variable levels of Th1 chemokines Mig, RANTES and MIP-1a were also found in these tumors, but their expression was weak, as a whole.
As with proinflammatory mediators, IL-1b and TNF-a were among the most amply expressed in all tumor samples, but with no appreciable differences among different groups. IL-6 expression was somewhat divergent, with the highest levels detected in one parental and one wt-affected tumor (Fig 5b) . Notably, all three IP10 vector-affected tumors displayed an elevated level of IL12p35 subunit expression, in contrast to contral samples (Fig 5b) . Taken together, these results are consistent with our immunohistological data (Fig 5a) , and suggest that infiltrated immune cells (i.e., TAMs) in different tumors may have distinct phenotypes or functions.
Discussion
In this study, we have explored an angiostatic approach of utilizing RCR vectors in achieving chronic delivery of human IP10. We show that bioactive, RCR-encoded human IP10 can be secreted from a variety of tumor cells, upon vector transduction. The level and duration of IP10 expression in vivo is sufficient to inhibit growth of s.c tumors and metastatic lesions, in both xenograft and syngeneic models. Furthermore, intratumoral expression of human IP10 impedes tumor neovascularization and curtails tumor cell mitotic activitiy. Collectively, these data suggest the feasibility of using RCR gene therapy for the chronic treatment of cancer as a more convenient alternative to the recombinant protein. 1, 2, 5, 10, 42 The use of angiostatic inhibitors has been postulated to help reverse the angiogenic switch and block the growth of tumor vascularization. [1] [2] [3] [4] [5] 7, 8, 10, 42 Recently, it was speculated that antiangiogenic agents may be more efficacious when they are continuously maintained at therapeutic levels in vivo. 5, 42 Indeed, initial experiments have shown that bolus injections of purified IP10 protein into Burkitt's lymphoma caused significant tumor vasculature damage and tumor necrosis in nude mice, but tumor inhibition was not achieved. 43 It was assumed that the antitumoral efficacy of IP10 may be more robust when the immunological mechanism could be Thirty-three days after tumor cell implantation, mice were killed and tissue fragments obtained from two parental (lanes 1 and 2) , three wttransduced (lanes 3-5), or three IP10-A-transduced tumors (lanes 6-8) established in C56BL/6 mice. Seven mouse cytokines (TNF-a, IL-6, IL1b, IL-10, IL-4, IFN-g, IL-12p35) and 4 chemokines (IP10, Mig, RANTES, MIP-1a) were analyzed by RT-PCR using 1 mg of total cellular RNA as template from individual tumor samples and specific primers, respectively as indicated in Table 1 . Specific primers for the G3PDH house-keeping gene were included in each reaction as a positive control. Overall, only subtle differences existed between the groups, with the exception that the IL-12p35 transcript was consistently expressed at elevated levels in IP10-transduced tumors. Controls were samples amplified without reverse transcriptase. No bands were obtained from these control samples.
Antiangiogenic gene therapy using RCR vector Y Sun et al integrated. 20 However, expression of IP10 in immunocompetent mice through a single or repeated intratumoral injection of adenoviral vectors encoding the IP10 gene had little impact on delaying tumor growth. 25, 26 We assumed that this lack of efficacy might be due to an immune response to the vectors and their low transduction efficiency, 30, 31 thus leading to insufficient, or more likely transient IP10 expression, because coinjection of both Ad-IP10 and Ad-IL-12 25 or the combined intravenous and intratumoral injection of an Ad-IP10 26 led to rejection of tumors in a large fraction of mice in these studies. In our study, we demonstrate that sustained in situ expression of IP10 following RCR gene transduction is sufficient to significantly retard tumor growth and metastasis in immunocompetent mice (Fig 3) . To our knowledge, this represents the first report on the therapeutic potential of RCR gene therapy in antiangiogenic strategies for treating cancer.
The therapeutic window of IP10 levels or doses for antitumoral effects remains to be illustrated; however, in our xenograft model in which the IP10-G vector is strictly confined to human HT1080 cells, we have been able to show that at least 15-36 ng/ml of IP10 is required to contain tumor growth. This is several orders above the levels of endogenous murine IP10. It is noteworthy that impaired tumor growth was also reported when the human Calu-1 tumor cell line (naturally expressing IP10) 44 or A375 tumor clones (retrovirally transduced with the IP10 gene) 27 were implanted into SCID and nude mice, respectively. Interestingly, similar observations are being made for another antiangiogenic inhibitor-endostatin: When endostatin was transfected into tumor cells that were then implanted into mice, tumor growth was virtually completely inhibited, associated with merely a modest (39 versus 11 ng/mg of protein) increase in endostatin level in tumor lysates, 29 whereas tumor growth inhibition was significantly less effective when endostatin was delivered by adenoviral vectors, although much higher amounts (1-10 mg/ml) of circulating endostatin were achieved. 28 These studies, together with ours, indicate on the one hand, that there may exist a proper range of levels/doses for these inhibitors to achieve therapeutic efficacy, and on the other hand, strongly support the notion that optimal antitumoral efficacy of these inhibitors requires timely and efficient in situ expression of the protein throughout the tumor bed.
Previously, continuous expression of IP10 by tumor cells transfected with IP10 cDNA was found to elicit strong T-cell-dependent antitumor immunity leading to the rejection of transfected tumors. 20 Tumor rejection occurred in immunocompetent but not immuno-compromised mice, and was accompanied by infiltration of lymphocytes and recruitment of inflammatory cells. In our study with the LLC tumor model, however, the antitumoral effects of IP10 seemed to be mainly mediated by its antiangiogenic properties, since both CD4 and CD8T cells were found to be scarce in IP10-affected tumors, an observation that correlated well with trace levels or no IFN-g (Th1) and IL-4 (Th2) mRNA detected (Fig 5b, and data not shown) . The reason for this discrepancy is presently unclear, but might be due to the differences in cell biology of different tumors or in the sensitivity/responsiveness of the host immune system to IP10. In our model, ample amounts of endogenous mouse IP10 mRNA have constantly been detected in tumor tissues, independent of RCR vector gene transduction (Fig 5b) . Moreover, variable amounts of gene transcripts for mouse Mig, RANTES, and MIP-1a, known to be able to chemoattract Th1 cells via CXCR3 or CCR5 receptor, 11, 12, [22] [23] [24] were evidenced. Such intrinsic Th1 chemokine expression profile of LLC tumors might be due to a stimulation 16, 45, 46 by abundant proinflammatory cytokines of tumor-associated endothelial cells, fibroblasts, and TAMs initially attracted and supported by tumor cell-released factors. [39] [40] [41] In fact, treatment of HUVECs with TNF-a and IL-1b and/or IL-6 stimulated the secretion of significant amounts of human IP10 protein in culture supernatant (data not shown). Whether expression and responsivenes of relevant chemokine receptor (i.e., CXCR3 and CCR5) is downregulated due to the lack of IL-2 12 or TGF-b activity 47 produced from tumors or TAMs, 39, 41, 47 or whether tumor/TAMs-derived TGF-b 39, 41, 47 and IL10 (in this study) induced T-cell anergy or apoptosis, remains to be determined. Whatever the reasons, however, the fact that the control tumors progressively grew, despite plenty of proinflammatory cytokines and TAMs present in tumor tissues, indicates that the local inflammation blunted overall innate and acquired antitumor immunity. 41 Keeping profound angiogenesis-promoting properties of proinflammatory cytokines in mind, [39] [40] [41] 47 it was not surprising that no complete tumor inhibition was achieved in our model system. This partial inhibitory effect in the situation of 100% tumor cell transduction by the RCR/IP10 vector further points to the difficulty of achieving significant therapeutic efficacy, when RCR/IP10 is to be injected to the established tumors where only a proportion of tumor cells can be transduced within a limited time period. Our data highlight a need to combine IP10 therapy with other antiangiogenic and/or immunotherapeutic approaches, to enhance antitumoral therapeutic efficacy. Efforts are under way in our laboratory to construct several new RCR vectors which will be combined with RCR/IP10 for treating established tumors.
It is of great importance that transduction of different tumor cells by RCR vectors did not appear to increase the levels of tumor-promoting properties, such as TAMs and proinflammatory cytokines (Fig 5) . [39] [40] [41] 47 On the contrary, the expression of RCR-delivered IP10 potentiated IL-12p35 transcription in 3 out of the 3 IP10 vectoraffected tumors. IL12 is known to be associated with antiangiogenic and immunostimulatory properties. The underlying mechanisms of action have not yet been defined. Although the potential of RCR vectors to amplify transgenes in different mouse models has been suggested by several studies, 32, 33 the present study provides first and important information on the immunological properties of RCR vectors in vivo.
The major concern in using RCR vectors in gene therapy is the control of their putative dissemination in the patient. However, MLV-derived RCR vector spread seems to be confined to immunosuppressive environment, such as tumor mass. In support of this hypothesis, recent studies have shown that the intratumoral injection of untargeted MLV-RCR vectors in nude mice led to progressive in situ vector transduction, but, with undetectable levels of extratumoral RCR spread. 32 Similar observations were made by Solly et al 33 who demonstrated rapid elimination of the virus in immunocompetent mice after intravenous injection of a replicative MLV vector. In our study, where IP10 vector may be released to the bloodstream during tumor growth, we did not observe any abnormalities of mice bearing IP10 vector-affected tumors, as compared with control mice, in terms of mouse general appearance and behavior, such as ruffling of fur and neuromuscular performance. On the other hand, it should be emphasized that these first-generation RCR vectors can be improved further. We 48 and others 49, 50 have recently shown that selective transduction of RCR vectors to tumor cells could be achieved by modifying viral Env or by incorporation of cell type-and tissuespecific transcriptional control elements. Precise redirecting the tropism of these vectors should upgrade their safety in vivo.
